Centogene NV represents values centered around innovation, collaboration, and excellence in the field of rare genetic diseases and diagnostics. With a philosophy rooted in personalized medicine, Centogene strives to improve patient outcomes by identifying and understanding rare diseases at a genetic level. By employing advanced technologies and leveraging extensive genetic data, Centogene aims to provide patients and healthcare professionals with accurate and timely diagnosis, enabling targeted therapies and enhancing overall quality of life. Centogene's commitment to continuous research, cutting-edge technology, and patient-centric approach positions the company as a leading player in the field of rare genetic diseases.

Centogene NV is primarily present in various countries and regions worldwide. The company operates in Europe, including Germany, Switzerland, and Austria, as well as the United States. Centogene NV's presence is also notable in the Middle East, with offices located in Dubai. Additionally, the company has a substantial presence in several Asian countries, such as India and Japan. Furthermore, Centogene NV extends its reach to Latin America, particularly in countries like Brazil and Mexico. The company's global presence allows it to provide comprehensive genetic testing and diagnostics services worldwide.

Centogene NV has achieved several significant milestones. The company, known for its pioneering work in the field of rare genetic diseases, has successfully established a vast genomic database that aids in the diagnosis and treatment of these conditions. Centogene NV has also developed proprietary technologies for genetic sequencing and analysis, ensuring accurate and timely results for patients worldwide. Moreover, the company has formed strategic partnerships with leading pharmaceutical and biotechnology firms, facilitating collaborative efforts in research and development. With its continuous focus on innovation and dedication to improving patient outcomes, Centogene NV has become a trusted name in the field of genetic diagnostics and rare diseases.

Centogene NV is a biotech company specializing in rare genetic diseases. Founded in 2006, Centogene has become a global leader in diagnostics and research for orphan diseases. The company uses genomic and clinical data to provide personalized insights to patients, physicians, and pharmaceutical companies. Centogene operates a state-of-the-art laboratory in Germany and serves patients and partners worldwide. With its extensive genetic database and advanced analytics, Centogene aims to accelerate the development of targeted therapies and improve patient outcomes. The company's commitment to cutting-edge research and innovation has positioned it as a trusted partner in the field of rare genetic diseases.

The main competitors of Centogene NV in the market are companies such as Invitae Corporation, Genomic Health Inc., and Myriad Genetics Inc.

Centogene NV is primarily active in the biotechnology and genetic diagnostics industries.

Centogene NV operates with a diagnostics business model. It specializes in rare diseases, offering genetic testing and analysis services to identify such conditions. Centogene NV uses advanced technologies and data analysis to provide insights into these diseases, aiming to improve patient outcomes and enhance the understanding of rare genetic disorders. By collaborating with pharmaceutical companies, Centogene NV contributes to the development of targeted therapies and personalized medicine. The company's comprehensive approach combines clinical data, genetic expertise, and vast databases to support the identification, diagnosis, and management of rare diseases. Centogene NV is committed to enabling early detection and accurate diagnosis for patients worldwide.

Centogene P/E suhe on −0,30.

Centogene KUV on 0,14.

AlleAktien kvaliteediskoor ettevõttele Centogene on 4/10.

oodatud Centogene käive on 60,69 mln. EUR.

oodatud Centogene kasum on −27,31 mln. EUR.

Centogene NV is a globally active company specializing in the development of diagnostic tests and solutions for rare genetic diseases. It offers a wide range of products including genetic tests, databases, analysis tools, and consulting services. The company works closely with patients, doctors, and researchers to develop solutions for the diagnosis and treatment of rare diseases. Centogene NV has a comprehensive network of partners and collaborations worldwide and operates laboratories in Europe and the US. Its key areas of focus include diagnostics, genetic databases, analysis tools and consulting services, as well as research and development. The company plays a crucial role in improving the understanding and treatment of rare diseases.

Centogene maksab dividendi 0 EUR, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu Centogene jaoks arvutada või ettevõte ei maksa dividende välja.

Centogene ISIN on NL0014040206.

Centogene WKN on A2PUCU.

Centogene tähis on CNTG.

Viimase 12 kuu jooksul maksis Centogene dividendi suuruses . See vastab ligikaudu dividenditootlusele. Järgneva 12 kuu jooksul maksab Centogene tõenäoliselt dividendi summas 0 EUR.

Centogene praegune dividenditootlus on .

Centogene maksab kvartaalset dividendi. See makstakse välja kuudel .

Centogene maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0 EUR. See vastab dividenditootlusele 0 %.

Centogene on liigitatud sektorisse 'Tervis'.

Viimase Centogene dividendide saamiseks 6.8.2024 suuruses 0 EUR pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 6.8.2024.

Viimane dividendimakse toimus 6.8.2024.

Aastal 2023 maksis Centogene 0 EUR dividende.

Centogene dividendid makstakse välja EUR.